Padmanee Sharma, M.D., Ph.D.

Peer-Reviewed Articles

1. Amit M, Baruch E, Nagarajan P, Gleber-Netto F, Rao X, Xie T, Akhter S, Adewale A, Islam S, Mattson B, Ferrarotto R, Wong M, Davies M, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunarante P, Goepfert R, Khushalani N, Wang J, Watowich S, Calin G, Migden M, Vermeer P, D'Silva N, Yaniv D, Burks J, Gomez J, Dougherty P, Tsai K, Allison J, Sharma P Wargo J, Myers J, Gross N. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by IL-6 blockade. Res Sq, 2023. e-Pub 2023. PMID: 37503252.
2. Chen HY, Zhao W, Na'ara S, Gleber-Netto FO, Xie T, Ali S, Thompson ZM, Buell J, Stafford H, Nagarajan P, Davies M, Wong MK, Migden MR, Sharma P, Myers JN, Gross ND, Amit M. Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer. JCO Precis Oncol 7:e2200490, 2023. e-Pub 2023. PMID: 37285560.
3. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A Phase 2 Study of Nivolumab Combined with Ibrutinib in Patients with Diffuse Large B-cell Richter Transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
4. Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36948506.
5. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 615(7953):E23, 2023. e-Pub 2023. PMID: 36894629.
6. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
7. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. e-Pub 2023. PMID: 36863962.
8. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P Wargo JA, Ariyan C, Tawbi HA. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 611(7934):155-160, 2022. e-Pub 2022. PMID: 36289334.
9. Sharma P, Allison JP. Immune checkpoint therapy: Forging ahead. Sci Transl Med 14(670):eadf2947, 2022. e-Pub 2022. PMID: 36350993.
10. Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. J Transl Med 20(1):271, 2022. e-Pub 2022. PMID: 35706041.
11. Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40(5):509-523.e6, 2022. e-Pub 2022. PMID: 35537412.
12. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase I-II trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on anti-angiogenic therapy. Sci Transl Med 14(641):eabm6420, 2022. e-Pub 2022. PMID: 35442707.
13. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 28(8):1735, 2022. e-Pub 2022. PMID: 35419587.
14. Siddiqui BA, Subudhi SK, Sharma P. Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer. Cell Rep Med 3(4):100613, 2022. e-Pub 2022. PMID: 35492243.
15. Goswami S, Siddiqui BA, Subudhi SK, Basu S, Yadav SS, Diab A, Sharma P. A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell 40(3):249-251, 2022. e-Pub 2022. PMID: 35290784.
16. Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 7(3):208-218, 2022. e-Pub 2022. PMID: 35065057.
17. Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 185(3):576, 2022. e-Pub 2022. PMID: 35120665.
18. Spencer CN, McQuade JL, Gopalakrishnan V, McCulloch JA, Vetizou M, Cogdill AP, Khan MAW, Zhang X, White MG, Peterson CB, Wong MC, Morad G, Rodgers T, Badger JH, Helmink BA, Andrews MC, Rodrigues RR, Morgun A, Kim YS, Roszik J, Hoffman KL, Zheng J, Zhou Y, Medik YB, Kahn LM, Johnson S, Hudgens CW, Wani K, Gaudreau PO, Harris AL, Jamal MA, Baruch EN, Perez-Guijarro E, Day CP, Merlino G, Pazdrak B, Lochmann BS, Szczepaniak-Sloane RA, Arora R, Anderson J, Zobniw CM, Posada E, Sirmans E, Simon J, Haydu LE, Burton EM, Wang L, Dang M, Clise-Dwyer K, Schneider S, Chapman T, Anang NAS, Duncan S, Toker J, Malke JC, Glitza IC, Amaria RN, Tawbi HA, Diab A, Wong MK, Patel SP, Woodman SE, Davies MA, Ross MI, Gershenwald JE, Lee JE, Hwu P, Jensen V, Samuels Y, Straussman R, Ajami NJ, Nelson KC, Nezi L, Petrosino JF, Futreal PA, Lazar AJ, Hu J, Jenq RR, Tetzlaff MT, Yan Y, Garrett WS, Huttenhower C, Sharma P, Watowich SS, Allison JP, Cohen L, Trinchieri G, Daniel CR, Wargo JA. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575):1632-1640, 2021. e-Pub 2021. PMID: 34941392.
19. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao JJ, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo EB, Allison JP, Yadav SS, Sharma P. A pilot study of Tremelimumab with or without cryoablation in patients with metastatic renal cell carcinoma. Nature Communications, 2021. e-Pub 2021. PMID: 34737281.
20. Abbas H, Hao D, Tomczak K, Barrodia P, Seon JI, Reville P, Alaniz Z, Wang W, Wang R, Wang F, Al-Atrash G, Takahashi K, Ning J, Ding M, Beird H, Matthews J, Little L, Zhang J, Basu S, Konopleva M, Marques-Piubelli ML, Sharma P, Solis L, Allison JP, Parra ER, Garcia-Manero G, Green M, Kornblau S, Lu W, Rai K, Tamegnon A, Wang L, Futreal A, Daver N. Single cell T cell Landscape and T Cell Receptor Repertoire Profiling of AML in Context of PD-1 Blockade Therapy. Nature Communications, 2021. e-Pub 2021. PMID: 34663807.
21. Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Jindal S, Tidwell RS, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone tumor microenvironment. J Immunother Cancer, 2021. e-Pub 2021. PMID: 34663638.
22. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 27(16):4557-4565, 2021. e-Pub 2021. PMID: 34187851.
23. Wang L, Sfakianos J, Beaumont K, Akturk G, Horowitz A, Sebra R, Farkas A, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh W, Szabo P, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, Bhardwaj N, Zhu J, Galsky M. Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing. Clinical Cancer Research, 2021. e-Pub 2021. PMID: 33837006.
24. Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12(1):5045, 2021. e-Pub 2021. PMID: 34413300.
25. Andrews MC, Duong CPM, Gopalakrishnan V, Iebba V, Chen WS, Derosa L, Khan MAW, Cogdill AP, White MG, Wong MC, Ferrere G, Fluckiger A, Roberti MP, Opolon P, Alou MT, Yonekura S, Roh W, Spencer CN, Curbelo IF, Vence L, Reuben A, Johnson S, Arora R, Morad G, Lastrapes M, Baruch EN, Little L, Gumbs C, Cooper ZA, Prieto PA, Wani K, Lazar AJ, Tetzlaff MT, Hudgens CW, Callahan MK, Adamow M, Postow MA, Ariyan CE, Gaudreau PO, Nezi L, Raoult D, Mihalcioiu C, Elkrief A, Pezo RC, Haydu LE, Simon JM, Tawbi HA, McQuade J, Hwu P, Hwu WJ, Amaria RN, Burton EM, Woodman SE, Watowich S, Diab A, Patel SP, Glitza IC, Wong MK, Zhao L, Zhang J, Ajami NJ, Petrosino J, Jenq RR, Davies MA, Gershenwald JE, Futreal PA, Sharma P, Allison JP, Routy B, Zitvogel L, Wargo JA. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med 27(8):1432-1441, 2021. e-Pub 2021. PMID: 34239137.
26. Lei M, Siemers N, Pandya D, Chang H, Sanchez T, Harbison C, Szabo P, Janjigian Y, Ott P, Sharma P, Bendell J, Evans TJ, de Braud F, Chau I, Boyd Z. Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab±Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. Clinical Cancer Research, 2021. e-Pub 2021. PMID: 33782030.
27. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34326169.
28. Demetri GD, Luke JJ, Hollebecque A, Powderly JD, Spira AI, Subbiah V, Naumovski L, Chen C, Fang H, Lai DW, Yue H, Polepally AR, Purcell JW, Robinson R, Sharma P, Allison JP, Tolcher A, Villalobos VM. First-in-Human Phase 1 Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical Cancer Research, 2021. e-Pub 2021. PMID: 33820780.
29. Sinha M, Zhang L, Subudhi SK, Chen B, Marquez J, Liu E, Allaire K, Cheung A, Ng S, Nguyen C, Friedlander T, Aggarwal R, Spitzer MH, Allison JP, Small EJ, Sharma P, Fong L. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prosate cancer. J Immunother Cancer, 2021. e-Pub 2021. PMID: 33986125.
30. Wei SC, Meijers WC, Axelrod ML, Anang NAS, Screever EM, Wescott EC, Johnson DB, Whitley E, Lehmann L, Courand PY, Mancuso JJ, Himmel LE, Lebrun-Vignes B, Wleklinski MJ, Knollmann BC, Srinivasan J, Li Y, Atolagbe OT, Rao X, Zhao Y, Wang J, Ehrlich LIR, Sharma P, Salem JE, Balko JM, Moslehi JJ, Allison JP. A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer Discov 11(3):614-625, 2021. e-Pub 2021. PMID: 33257470.
31. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2021. PMID: 33187886.
32. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell M, Slack Tidwell R, Guo CC, Kamat AM, Matin S, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami A, Sharma P. Neoadjuvant combination PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature Medicine, 2020. e-Pub 2020. PMID: 33046869.
33. Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell, 2020. e-Pub 2020. PMID: 32916128.
34. Galsky MD, Saci A, Szabo PM, Han GC, Grossfeld G, Collette S, Siefker-Radtke A, Necchi A, Sharma P. Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clin Cancer Res. e-Pub 2020. PMID: 32532789.
35. Goswami S, Chen Y, Anandhan S, Szabo PM, Basu S, Blando JM, Liu W, Zhang J, Natarajan SM, Xiong L, Guan B, Yadav SS, Saci A, Allison JP, Galsky MD, Sharma P. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci Transl Med 12(548), 2020. e-Pub 2020. PMID: 32554706.
36. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 12(537), 2020. e-Pub 2020. PMID: 32238575.
37. Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. e-Pub 2020. PMID: 32359397.
38. Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PA. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun 11(1):1839, 2020. e-Pub 2020. PMID: 32296058.
39. Oran B, Garcia-Manero G, Saliba RM, Alfayez M, Al-Atrash G, Ciurea SO, Jabbour EJ, Mehta RS, Popat UR, Ravandi F, Alousi AM, Kadia TM, Konopleva M, DiNardo CD, Rezvani K, Shpall EJ, Sharma P, Kantarjian HM, Champlin RE, Daver N. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. e-Pub 2020. PMID: 32125707.
40. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist 25(3):252-258, 2020. e-Pub 2020. PMID: 32162795.
41. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
42. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med 26(1):39-46, 2020. e-Pub 2020. PMID: 31873309.
43. Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. e-Pub 2020. PMID: 31925406.
44. Sharma P, Sohn J, Shin SJ, Oh DY, Keam B, Lee HJ, Gizzi M, Kalinka E, FYFL DV, Ruscica D, Ferro S, Xiao F, Baverel P, Chen CC, Asubonteng K, Morsli N, Dirix L. Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. Clin Cancer Res 26(1):61-70, 2020. e-Pub 2020. PMID: 31801732.
45. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. e-Pub 2020. PMID: 31942075.
46. Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, Wang J, Blando J, Byers LA, Yanamandra N, Brett S, Morley P, Sharma P, Allison J, Wistuba II, Heymach JV. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J Immunother Cancer 7(1):351, 2019. e-Pub 2019. PMID: 31843013.
47. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res 7(12):1903-1909, 2019. e-Pub 2019. PMID: 31658994.
48. Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, Sharma P. Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. Cell 179(5):1177-1190.e13, 2019. e-Pub 2019. PMID: 31730856.
49. de Groot J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, Pei B, O'brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. e-Pub 2019. PMID: 31755915.
50. Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, Allison JP, Sharma P. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A 116(44):22246-22251, 2019. e-Pub 2019. PMID: 31611368.
51. Ravandi F, Assi R, Daver N, Benton CB, Kadia T, Thompson PA, Borthakur G, Alvarado Y, Jabbour EJ, Konopleva M, Takahashi K, Kornblau S, DiNardo CD, Estrov Z, Flores W, Basu S, Allison J, Sharma P, Pierce S, Pike A, Cortes JE, Garcia-Manero G, Kantarjian HM. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol 6(9):e480-e488, 2019. e-Pub 2019. PMID: 31400961.
52. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist. e-Pub 2019. PMID: 31501271.
53. Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey JN, Allison JP, Sharma P. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunol Res 7(9):1390-1395, 2019. e-Pub 2019. PMID: 31289040.
54. Shi LZ, Goswami S, Fu T, Guan B, Chen J, Xiong L, Zhang J, Ng Tang D, Zhang X, Vence L, Blando J, Allison JP, Collazo R, Gao J, Sharma P. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. e-Pub 2019. PMID: 31466995.
55. Vence L, Bucktrout SL, Fernandez Curbelo I, Blando J, Smith BM, Mahne AE, Lin JC, Park T, Pascua E, Sai T, Chaparro-Riggers J, Subudhi SK, Borin Scutti J, Higa MG, Zhao H, Yadav SS, Maitra A, Wistuba II, Allison JP, Sharma P. Characterization and comparison of GITR expression in solid tumors. Clin Cancer Res. e-Pub 2019. PMID: 31358539.
56. Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol. e-Pub 2019. PMID: 31272788.
57. Sharma A, Subudhi SK, Blando J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers-Response. Clin Cancer Res 25(11):3469-3470, 2019. e-Pub 2019. PMID: 31160495.
58. Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G. Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. Int J Clin Oncol. e-Pub 2019. PMID: 31218529.
59. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114:67-75, 2019. e-Pub 2019. PMID: 31075726.
60. Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA, Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Saci A, Callahan MK, Rosenberg J. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol:JCO1900538. e-Pub 2019. PMID: 31100038.
61. Wei SC, Sharma R, Anang NAS, Levine JH, Zhao Y, Mancuso JJ, Setty M, Sharma P, Wang J, Pe'er D, Allison JP. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity 50(4):1084-1098.e10, 2019. e-Pub 2019. PMID: 30926234.
62. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study. Cancer Discov 9(3):370-383, 2019. e-Pub 2019. PMID: 30409776.
63. Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clin Cancer Res 25(4):1233-1238, 2019. e-Pub 2019. PMID: 30054281.
64. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 25(1):188, 2019. e-Pub 2019. PMID: 30479380.
65. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A 116(5):1692-1697, 2019. e-Pub 2019. PMID: 30635425.
66. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1941, 2018. e-Pub 2018. PMID: 30361510.
67. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1942, 2018. e-Pub 2018. PMID: 30361511.
68. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24(12):1804-1808, 2018. e-Pub 2018. PMID: 30420754.
69. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. e-Pub 2018. PMID: 30500073.
70. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. e-Pub 2018. PMID: 30297909.
71. Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol:JCO2017766212. e-Pub 2018. PMID: 30110194.
72. Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun 9(1):3503, 2018. e-Pub 2018. PMID: 30158554.
73. Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, Fu S, Sharma P, Meric-Bernstam F, Naing A. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs 36(4):601-607, 2018. e-Pub 2018. PMID: 29075985.
74. Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Sharma P, Mendoza T, Patel A, Thirumurthi S, Sheshadri A, Meric-Bernstam F, Naing A. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36(4):638-646, 2018. e-Pub 2018. PMID: 29159766.
75. Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. e-Pub 2018. PMID: 29905573.
76. Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ, investigators C. Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]. Eur Urol 73(4):e116-e118, 2018. e-Pub 2018. PMID: 29306512.
77. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, Investigators C. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 378(14):1277-1290, 2018. e-Pub 2018. PMID: 29562145.
78. Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL, Vence LM, Allison JP, Gulbis AM, Sharma P. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res 24(5):1011-1018, 2018. e-Pub 2018. PMID: 29246938.
79. Hailemichael Y, Woods A, Fu T, He Q, Nielsen MC, Hasan F, Roszik J, Xiao Z, Vianden C, Khong H, Singh M, Sharma M, Faak F, Moore D, Dai Z, Anthony SM, Schluns KS, Sharma P, Engelhard VH, Overwijk WW. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. e-Pub 2018. PMID: 29480817.
80. Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, Yuan J, Jungbluth A, Blando J, Sharma P, Rudensky AY, Wolchok JD, Allison JP. Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res 6(2):189-200, 2018. e-Pub 2018. PMID: 29339377.
81. Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. Nat Med 24(2):123-124, 2018. e-Pub 2018. PMID: 29414936.
82. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. PMID: 29361468.
83. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359(6371):97-103, 2018. e-Pub 2018. PMID: 29097493.
84. Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver N. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice. Adv Exp Med Biol 995:97-116, 2018. e-Pub 2018. PMID: 30539507.
85. Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, Bodenmiller B, Campbell P, Carninci P, Clatworthy M, Clevers H, Deplancke B, Dunham I, Eberwine J, Eils R, Enard W, Farmer A, Fugger L, Göttgens B, Hacohen N, Haniffa M, Hemberg M, Kim S, Klenerman P, Kriegstein A, Lein E, Linnarsson S, Lundberg E, Lundeberg J, Majumder P, Marioni JC, Merad M, Mhlanga M, Nawijn M, Netea M, Nolan G, Pe'er D, Phillipakis A, Ponting CP, Quake S, Reik W, Rozenblatt-Rosen O, Sanes J, Satija R, Schumacher TN, Shalek A, Shapiro E, Sharma P, Shin JW, Stegle O, Stratton M, Stubbington MJT, Theis FJ, Uhlen M, van Oudenaarden A, Wagner A, Watt F, Weissman J, Wold B, Xavier R, Yosef N, Meeting Participants HCA. The Human Cell Atlas. Elife 6, 2017. e-Pub 2017. PMID: 29206104.
86. Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, George S. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. Eur Urol 72(3):368-376, 2017. e-Pub 2017. PMID: 28410865.
87. Tetzlaff MT, Jazaeri AA, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients. J Cutan Pathol. e-Pub 2017. PMID: 28901560.
88. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170(6):1120-1133.e17, 2017. e-Pub 2017. PMID: 28803728.
89. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE. Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 5(1):80, 2017. e-Pub 2017. PMID: 28962591.
90. Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 5(1):68, 2017. e-Pub 2017. PMID: 28807024.
91. Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A. Safety and Efficacy of Nivolumab in Combination with Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol:JCO2016721985. e-Pub 2017. PMID: 28678668.
92. Blasutig IM, Farkona S, Buchbinder EI, Luke JJ, Sharma P, Sznol M. The Phoenix Rises: The Rebirth of Cancer Immunotherapy. Clin Chem 63(7):1190-1195, 2017. e-Pub 2017. PMID: 28515097.
93. Reuben A, Gittelman RM, Gao J, Zhang J, Yusko E, Wu CJ, Emerson R, Zhang J, Tipton CM, Li J, Quek K, Gopalakrishnan V, Chen R, Vence L, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher SG, Heymach J, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: an Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. e-Pub 2017. PMID: 28733428.
94. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 23(5):551-555, 2017. e-Pub 2017. PMID: 28346412.
95. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446-453, 2017. e-Pub 2017. PMID: 28223062.
96. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, JÁ A, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (Checkmate 275) : a multicentre, single-arm, phase 2 trial. Lancet Oncol 18(3):312-322, 2017. e-Pub 2017. PMID: 28131785.
97. Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res 23(6):1388-1396, 2017. e-Pub 2017. PMID: 27649551.
98. Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Gurney H, Donskov F, Peltola K, Wagstaff J, Gauler TC, Ueda T, Zhao H, Waxman IM, Motzer RJ, investigators C. CheckMate 025 randomized Phase 3 Study: Outcomes by key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. Eur Urol. e-Pub 2017. PMID: 28262413.
99. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9(379), 2017. e-Pub 2017. PMID: 28251903.
100. Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature 543(7647):728-732, 2017. e-Pub 2017. PMID: 28321130.
101. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res 77(4):839-850, 2017. e-Pub 2017. PMID: 27821490.
102. Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A. Metastatic melanoma patient had complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunol Res 5(2):100-105, 2017. e-Pub 2017. PMID: 28062513.
103. Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun 8:14340, 2017. e-Pub 2017. PMID: 28194010.
104. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2, 2017. e-Pub 2017. PMID: 28819565.
105. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35, 2017. e-Pub 2017. PMID: 28428884.
106. McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clin Cancer Res 22(23):5729-5737, 2016. e-Pub 2016. PMID: 27566765.
107. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, de Braud F, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17(11):1590-1598, 2016. e-Pub 2016. PMID: 27733243.
108. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919-11924, 2016. e-Pub 2016. PMID: 27698113.
109. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell 167(2):397-404.e9, 2016. e-Pub 2016. PMID: 27667683.
110. Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol 9(1):81, 2016. e-Pub 2016. PMID: 27595932.
111. Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nat Commun 7:12335, 2016. e-Pub 2016. PMID: 27498556.
112. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
113. Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP, Feldman RM. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. Cancer Res 76(13):3684-9, 2016. e-Pub 2016. PMID: 27197182.
114. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17(7):883-95, 2016. e-Pub 2016. PMID: 27269741.
115. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 5(3):e1136044, 2016. e-Pub 2016. PMID: 27141370.
116. Bilen MA, Subudhi SK, Gao J, Tannir NM, Tu SM, Sharma P. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer 4:36, 2016. e-Pub 2016. PMID: 27330809.
117. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, Investigators C. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma. N Engl J Med 373(19):1803-13, 2015. e-Pub 2015. PMID: 26406148.
118. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res 3(9):1017-29, 2015. e-Pub 2015. PMID: 26014097.
119. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS - mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 5(8):860-77, 2015. e-Pub 2015. PMID: 26069186.
120. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 7(9):967-80, 2015. e-Pub 2015. PMID: 26310908.
121. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis stimulates immunosuppression and accelerates pancreatic cancer with diminished survival. Cancer Cell 25(6):719-34, 2014. e-Pub 2014. PMID: 24856586.
122. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med 211(4):715-25, 2014. e-Pub 2014. PMID: 24687957.
123. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash G. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2(4):361-70, 2014. e-Pub 2014. PMID: 24764583.
124. Chen H, Fu T, Suh WK, Tsavachidou D, Wen S, Gao J, Ng Tang D, He Q, Sun J, Sharma P. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy. Cancer Immunol Res 2(2):167-76, 2014. e-Pub 2014. PMID: 24778280.
125. Plimack ER, Desai JR, Issa JP, Jelinek J, Sharma P Vence LM, Bassett RL, Ilagan JL, Papadopoulos NE, Hwu WJ. A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Invest New Drugs. e-Pub 2014.
126. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 1:229-234, 2013. e-Pub 2013.
127. Richey SL, Tamboli P, NG CS, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II trial of Pemetrexed plus Gemcitabine in patients with locally advanced and metastatic non-clear cell renal cell carcinoma. Am J Clin Oncol, 2012. e-Pub 2012. PMID: 22706175.
128. Sun J, Tang DN, Fu T, Sharma P. Identification of human regulatory T cells in the setting of T cell activation and anti-CTLA-4 immunotherapy based on expression of latency associated peptide (LAP). Cancer Discov 2(2):122-30, 2012. e-Pub 2012. PMID: 22585857.
129. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal anti-tumor responses mediated by anti-CTLA-4 therapy. Cancer Res 71(16):5445-54, 2011. e-Pub 2011. PMID: 21708958.
130. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med 9(1):214, 2011. e-Pub 2011. PMID: 22168571.
131. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-71, 2010. e-Pub 2010. PMID: 20460488.
132. Matin SF, Sharma P, Gill IS, Tannenbaum C, Hobart MG, Novick AC, Finke JH. Immunologic response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. J Urol 183(1):333-8, 2010. e-Pub 2010. PMID: 19914660.
133. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA vaccine induces T cell responses that are suppressed by regulatory T cells. Clin Cancer Res 15(6):2130-9, 2009. e-Pub 2009. PMID: 19276258.
134. Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-{gamma} levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8):2729-34, 2009. e-Pub 2009. PMID: 19202079.
135. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother 31(9):849-57, 2008. e-Pub 2008. PMID: 18833002.
136. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi T cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105(39):14987-92, 2008. e-Pub 2008. PMID: 18818309.
137. Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 8:9, 2008. e-Pub 2008. PMID: 18503261.
138. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 104(49):19458-63, 2007. e-Pub 2007. PMID: 18042703.
139. Kopetz S, Jimenez CA, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Resp J 29(4):813-5, 2007. e-Pub 2007. PMID: 17400880.
140. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 104(10):3967-72, 2007. e-Pub 2007. PMID: 17360461.
141. Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ, Jungbluth AA. Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res 12(18):5442-7, 2006. e-Pub 2006. PMID: 17000678.
142. Sharma P, Gnjatic S, Jungbluth AA, Williamson B, Herr H, Stockert E, Dalbagni G, Donat SM, Reuter VE, Santiago D, Chen YT, Bajorin DF, Old LJ. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T cell epitope in a patient with bladder cancer. Cancer Immun 3:19, 2003. e-Pub 2003. PMID: 14680360.
143. Sharma P, Page MJ, Poritz LS, Koltun WA, Chorney MJ. An increased gamma delta T cell population in the intestine of thymus-leukemia antigen transgenic mice. Cell Immunol 176(2):153-7, 1997. e-Pub 1997. PMID: 9073388.
144. Sharma P, Johnson CA, Bonneau RH, Lang CM, Chorney MJ. Transgenic mice expressing the thymus leukemia antigen fail to control cutaneous herpes simplex virus infection. Cell Immunol 174(1):84-9, 1996. e-Pub 1996. PMID: 8929457.
145. Joyce S, Negishi I, Boestanu A, DeSilva DA, Sharma P, Chorney MJ, Loh DY, Van Kaer L. Expansion of natural (NK1+) T cells that express alpha/beta T-cell receptors in transporters associated with antigen presentation-1 null and thymus-leukemia antigen positive mice. J Exp Med 184(4):1579-84, 1996. e-Pub 1996. PMID: 8879233.
146. Venditti CP, Lawlor DA, Sharma P, Chorney MJ. Structure and content of the major histocompatibility complex (MHC) class I regions of the great anthropoid apes. H Immunol 49(2):71-84, 1996. e-Pub 1996. PMID: 8872161.
147. Sharma P, Joyce S, Chorney K, Griffith J, Bonneau RH, Wilson F, Flavell R, Chorney MJ. Thymus-leukemia antigen, T18d, interacts with T cells and self peptides. J Immunol 156(3):987-96, 1996. e-Pub 1996. PMID: 8558026.

Invited Articles

1. Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma:1-13. e-Pub 2017. PMID: 28679300.
2. Goswami S, Sharma P. Genetic biomarker for cancer immunotherapy. Science 357(6349):358, 2017. e-Pub 2017. PMID: 28751597.
3. Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168(4):707-723, 2017. e-Pub 2017. PMID: 28187290.
4. Masarova L, Kantarjian H, Garcia-Mannero G, Ravandi F, Sharma P, Daver N. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol 995:73-95, 2017. e-Pub 2017. PMID: 28321813.
5. Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 41:23-31, 2016. e-Pub 2016. PMID: 27240055.
6. Sharma P. Immune Checkpoint Therapy and the Search for Predictive Biomarkers. The Cancer Journal 22(2):68-72, 2016. e-Pub 2016.
7. Neelapu SS, Sharma P. Targeting the tumor niche to treat cancer. Proc Natl Acad Sci U S A 112(42):12907-8, 2015. e-Pub 2015. PMID: 26450879.
8. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 348(6230):56-61, 2015. e-Pub 2015. PMID: 25838373.
9. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161(2):205-14, 2015. e-Pub 2015. PMID: 25860605.
10. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. Cancer Immunol Res 2(9):831-8, 2014. e-Pub 2014. PMID: 25187273.
11. Harshman LC, Drake CG, Wargo JA, Sharma P, Bhardwaj N. Cancer Immunotherapy Highlights from the 2014 ASCO Meeting. Cancer Immunol Res 2(8):714-9, 2014. e-Pub 2014. PMID: 25092813.
12. Raval RR, Sharabi AB, Walker AJ, Drake CG, P| S. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer 2:14, 2014. e-Pub 2014. PMID: 24883190.
13. Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene. e-Pub 2013. PMID: 24276248.
14. Gao JJ, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol 34(2):90-8, 2013. e-Pub 2013. PMID: 23031830.
15. Sharma P, Logothetis C. Prostate cancer: Combination of vaccine plus ipilimumab-safety and toxicity. Nat Rev Urol 9(6):302-3, 2012. e-Pub 2012. PMID: 22565371.
16. Gerritsen WR, Sharma P. Current and emerging treatment options for castration-resistant prostate cancer: A focus on immunotherapy. J Clin Immunol 32(1):25-35, 2012. e-Pub 2012. PMID: 22048979.
17. Sharma P, Allison JP. Retrospective. Lloyd J. Old (1933-2011). Science 335(6064):49, 2012. e-Pub 2012. PMID: 22223799.
18. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer 11(11):805-12, 2011. e-Pub 2011. PMID: 22020206.
19. Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P. Cancer immunotherapy: Sipuleucel-T and beyond. Pharmacotherapy 31(8):813-28, 2011. e-Pub 2011. PMID: 21923608.
20. Sharma P. Cancer immunotherapy: In vivo imaging of adoptively transferred T cells in an immunocompetent host. Proc Natl Acad Sci U S A 107(32):13977-8, 2010. e-Pub 2010. PMID: 20671198.
21. Mittendorf EA, Sharma P. Mechanisms of T cell inhibition: Implications for cancer immunotherapy. Expert Rev Vaccines 9(1):89-105, 2010. e-Pub 2010. PMID: 20021308.
22. Carthon B, Sharma P. Advanced urothelial carcinoma: Current treatment strategies and novel agents in clinical trials. CML Urology 14:57-68, 2009. e-Pub 2009. PMID: 20460488.
23. Aparicio A, Sharma P, Millikan RE. Experimental systemic therapy of metastatic urothelial cancer. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, 2009. e-Pub 2009.
24. Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in bladder cancer. Cancer Immun 7:10, 2007. e-Pub 2007. PMID: 17591743.
25. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high risk bladder cancer. Semin Oncol 34(2):165-72, 2007. e-Pub 2007. PMID: 17382800.
26. Pagliaro LC, Sharma P. Review of treatment strategies for metastatic bladder cancer. Minerva Urol Nefrol 58:53-71, 2006. e-Pub 2006. PMID: 16760884.
27. Sharma P, Donat MS, Herr H, Bajorin D. Treatment of locally advanced bladder cancer. Princ Prac Oncol Updates 16:8, 2001. e-Pub 2001.

Review Articles

1. Khanmammadova N, Islam S, Sharma P, Amit M. Neuro-immune interactions and immuno-oncology. Trends Cancer 9(8):636-649, 2023. e-Pub 2023. PMID: 37258398.
2. Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP. Immune checkpoint therapy-current perspectives and future directions. Cell 186(8):1652-1669, 2023. e-Pub 2023. PMID: 37059068.
3. Goswami S, Anandhan S, Raychaudhuri D, Sharma P. Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol 23(2):106-120, 2023. e-Pub 2023. PMID: 35697799.
4. Michielin O, Lalani AK, Robert C, Sharma P, Peters S. Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. J Immunother Cancer 10(1), 2022. e-Pub 2022. PMID: 35078922.
5. Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184(21):5309-5337, 2021. e-Pub 2021. PMID: 34624224.
6. Sharma P, Siddiqui BA, Anandhan S, Yadav SS, Subudhi SK, Gao J, Goswami S, Allison JP. The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11(4):838-857, 2021. e-Pub 2021. PMID: 33811120.
7. Rouanne M, Bajorin DF, Hannan R, Galsky MD, Williams SB, Necchi A, Sharma P, Powles T. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol 3(6):728-738, 2020. e-Pub 2020. PMID: 33177001.
8. Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32(5):1094-1105, 2018. e-Pub 2018. PMID: 29487386.
9. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34(43):5411-7, 2015. e-Pub 2015. PMID: 25659583.
10. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. State of the science: an update on renal cell carcinoma. Mol Cancer Res 10(7):859-80, 2012. e-Pub 2012. PMID: 22638109.

Editorials

1. Sharma P. From the Guest Editor: Immune Checkpoint Therapy as a Weapon Against Cancer. Cancer J 22(2):67, 2016. PMID: 27111899.

Abstracts

1. Mitra A, Andrews M, Roh W, de Macedo M, Reuben A, Carapeto F, Wang F, Reddy S, Wani K, Spencer C, Miller J, Schalck A, Little L, Sakellariou-Thompson D, Gumbs C, Hwu WJ, Bernatchez C, Zhang J, Hwu P, Navin N, Sharma P, Allison JP, Wargo J, Lazar AJ, Futreal A. Spatially resolved immunogenomic analyses reveal diverse sub tumoral microenvironments in the context of melanoma immunotherapy. American Association for Cancer Research, 2019. e-Pub 2019.
2. Gopalakrishnan V, Andrews M, Chen W, Spencer C, Vence L, Reuben A, Cooper Z, Prieto P, Tetzlaff M, Khan M, Lazar A, Hudgens C, Haydu L, Hussein A, Tawbi H, Hwu P, Hwu W, Amaria R, Burton E, Woodman S, Diab A, Patel S, Glitza I, Zhang J, Petrosino J, Jenq R, Davies M, Gershenwald J, Sharma P, Allison JP, Futreal A, Wargo J. Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome. American Association for Cancer Research, 2019. e-Pub 2019.
3. Reddy SM, Helmink B, Gao J, Zhang S, Yizhak K, Sade-Feldman M, Basar R, Blando J, Han G, Gopalakrishnan V, Zhao H, Liu W, Tawbi H, Amari R, Davies M, Gershenwald J, Burton E, Allison JP, Tetzlaff M, Rezvan K, Hacohen N, Sharma P, Wang L, Wargo J. Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors. American Association for Cancer Research, 2019. e-Pub 2019.
4. Campbell MT, Martin S, Tam AL, Sheth RA, Sing S, Ahrar K, Slack Tidwell B, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Shah AY, Blando JM, Duan F, Basu S, Allison J, Sharma P. A pilot study of tremelimumab (treme) with or without Cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC). European Society for Medical Oncology, 2019. e-Pub 2019.
5. Helmink B, Reddy S, Blando J, Liang Y, Warren S, Gopalakrishnan V, Tawbi H, Amaria R, Davies M, Gershenwald J, Burton E, Basar R, Lazar A, Hudgens C, Rezvani K, Allison JP, Sharma P, Beechem J, Wargo J, Tetzlaff M. NanoString®GeoMx®digital spatial profiling further defines the role of B cells in the response to immune checkpoint blockade. American Association for Cancer Research, 2019. e-Pub 2019.
6. Kaseb A, Pestana RC, Vence L, Blando J, Yadav S, Ikoma N, Vauthey J, Allison JP, Sharma P. Perioperative Phase II Study Evaluating Nivolumab Alone versus Nivolumab plus Ipilimumab in Patients with Resectable HCC. Gastrointestinal Cancers Symposium, 2019. e-Pub 2019.
7. Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav K, Morris V, Sharma P, Allison J, Blando J, Mar D, Lizee G, Janku F, Overman M, Kopetz S. Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts). American Society of Clinical Oncology, 2019. e-Pub 2019.
8. Daver NG, Garcia-Manero G, Konopleva MY, Alfayez M, Pemmaraj N, Kadia TM, DiNardo CD, Cortes JE, Ravandi F, Abbas H, Basu S, Jabbour E, Pierce SA, Estrov ZE, Takahashi K, Ning J, Kornblau SM, Sasaki K, Masarova L, Flores W, Allison JP, Sharma P Kantarjian HM. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2. American Society of Hematology, 2019. e-Pub 2019.
9. Gao J, Siefker-Radtke AO, Navai N, Campbell MT, Tidwell RS, Guo C, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Blando JM, Vence LM, Duan F, Basu S, Singh S, Zhao H, Allison JP, Dinney C, Sharma P. A pilot presurgical study evaluation anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). American Society of Clinical Oncology, 2019. e-Pub 2019.
10. Lei M, Siemers N, Pandya D, Chang H, Sanchez T, Dorange C, Harbison C, Szabo P, Janjigian Y, Ott P, Sharma P, Bendell J, Evans J, de Braud F, Chau I, Boyd Z. Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC). American Association for Cancer Research, 2019. e-Pub 2019.
11. Gao J, Karam JA, Tannir N, Campbell M, Tidwell RS, Ahrar K, Priya Rao P, Ng C, Jonasch E, Matin S, Zurita A, Shah AY, Shen Y, Blando JM, Vence LM, Basu S, Zhao H, Allison JP, Wood CG, Sharma P. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). American Society of Clinical Oncology, 2019. e-Pub 2019.
12. Kaseb AO, Pestana RC, Vence LM, Blando JM, Singh S, Ikoma N, Raghav KPS, Sakamuri D, Girard L, Tan D, J-N V, C-WD T, Aloia TA, Chun YS, Yao JC, Wolff RA, Allison JP, Sharma P. Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. American Society of Clinical Oncology, 2019. e-Pub 2019.
13. Goswami S, Basu S, Sharma P. A potential biomarker for anti-PD-1 immunotherapy. Nat Med 24(2):123-124, 2018. e-Pub 2018. PMID: 29414936.
14. Sharma P, Baron A, Necchi A, Plimack ER, Pal SK, Bedke J, Arranz JA, Vaena D, Grimm MO, Bracarda S, Retz M, Radtke AS, Ohyama C, Grossfeld G, Lu H, Saci A, Tang H, Galsky MD. Nivolumab monotherapy in patients with advanced platinum‐resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275. American Association for Cancer Research Annual Meeting, 2018. e-Pub 2018.
15. Daver NG, Basu S, Garcia-Manero G, Cortes JE, Ravandi F, Jabbour E, Hendrickson S, Brandt M, Peirce S, Gordon T, Pemmaraju N, Andreeff M, Ning J, Kornblau S, Kadia TM, Dinardo CD, Konopleva M, Allison JP, Kantarjian HM, Sharma P. Phase IB/II Study of Nivolumab with Azacytidine (AZA) in Patients (pts) with Relapsed AML. American Society for Clinical Oncology, 2017. e-Pub 2017.
16. Janjigian YY, Ott PA, Calvo E, Kim JW, Ascierto PA, Sharma P, Peltola KJ, Jaeger D, Evans J, De Braud FG, Chau I, Tschaika M, Harbison CT, Cai W, Bendell JC, Le DT. Nivolumab+Ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory(CTx-R) gastric (G), esophagel (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. American Society for Clinical Oncology, 2017. e-Pub 2017.
17. Subudhi SK, Aparici A, Troncoso P, Zhang J, Gumbs C, WU CJ, Gao JJ, Vence LM, Blando JM, Corn PG, Araugo JC, Zurita AJ, Prokhorova IN, Van Alstine M, Logothetis C, Futreal A, Allison JP, Sharma P. Linking Tumor Mutational Load to Clinical Responses to Ipilimumab (IPI) in Men with Advanced Prostate Cancer (PCa). American Society for Clinical Oncology, 2017. e-Pub 2017.
18. Sharma P, Sohn JH, Shin SJ, Oh D, Keam B, Lee HJ, Canon JL, Kalinka-Warzocha E, Langenberg M, Allison J, Ben Y, Kataria R, Ferro S, Asubonteng K, Dirix L. Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma. SITC 2017 Annual Meeting Abstracts Book:301-302, 2017. e-Pub 2017.
19. Gao JJ, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncosco P, Allison JP, Logothetis C, Wistuba II, Wargo JA Blando JM, Sepulveda MA< Sun JJ, Sharma P. Investigation of Mechanisms of Resistance to Ipilimumab Thearapy with a Pre-surgical Trial in Patients with High-Risk, Localized Prostate Cancer. American Society for Clinical Oncology, 2017. e-Pub 2017.
20. Shah AY, Gao JJ, Lemke E, Campbell MT, Qurita AJ, Wang J, Corn PG, Jonasch E, Sharma P, Tannir NM. Responses to second-line tyrosine kinase inhibitors after first-line immune checkpoint inhibitors in advanced renal cell carcinoma. American Society for Clinical Oncology, 2017. e-Pub 2017.
21. Necchi A, Grimm MO, Retz M, Arija JAA, Bracarda S, Bedke J, Baron AD, Sharma P, Galsky MD, Vaena DA, Kalinka-Warzocha E, Cwikiel M, Pal SK, Morales R, Taylor F, Gooden KM, Plimack ER. Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275. American Society for Clinical Oncology, 2017. e-Pub 2017.
22. Gao JJ, Karam JA, Wood CG, Matin S, Ahrar K, Jonasch E, Tannir N, Campbell M, Ng C, Slack R, Rao P, Allison JP, Blando JM, Vence LM, Basu S, Zhao H, Chen T, Chen H, Sharma P. Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilumumab in metastatic renal cell carcinoma. American Association for Cancer Research, 2017. e-Pub 2017.
23. Reiller M, Basu S, Katkhuda R, Patterson N, Blanco JM, Menter D, Allison JA, Kopetz S, Sharma P, Overman MJ. Prognostic implications of TAMs in colorectal cancer hepatic metastases. American Society for Clinical Oncology, 2017. e-Pub 2017.
24. Wargo JA, Gopalakrishnan V, Spencer C, Karpinets T, Reuben A, Andrews MC, Tetzlaff MT, Lazar A, Hwu P, Hwu WJ, Glitza IC, Tawbi HAH, Patel SP, Lee JE, Davies MA, Gershenwald JE, Furtreal A, Sharma P, Allison JP, Jenq RR. Diversity and composition of the gut microbiome are associated with enhanced responses and improved progression=free survivak (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. American Society for Clinical Oncology, 2017. e-Pub 2017.
25. Chen WS, Andrew MC, Spencer C, Tawbi HAH, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria RN, Burton EM, Woodman SE, Davies JE, Sharma P, Allison JP, Futreal A, Wargo JA. Molecular and immune predictors of response and toxicity to combined CTLA-4 and PD-1 blockade in metastatic melonoma (MM) patients(pts). American Society for Clinical Oncology, 2017. e-Pub 2017.
26. Davar NG, Garcia-Manero G, Cortes JE, Basu S, Ravandi F, Kadia TM, Borthakyr G, Jabbour E, Dinardo CD, Pemmaraju N, Brandt M, Pierce S, Hussin N, Kornblau SM, Andreef M, Konopleva M, Ning J, Allison JP, Sharma P, Kantarjian HM. Phase IB/II Study of Lirilumab with Azacytidine (AZA) in Relapsed AML. American Society for Clinical Oncology, 2017. e-Pub 2017.
27. Khouri IF, Curbelo IF, Turturro F, milton DR, Kim RA, Jabbour EJ, Bassett RL, Vence LM, P S, Gulbis AM. Lenalidomide alternating with ipilimumab for lymphoma and chronic lymphocytic leukemia after allogeneic or autologous stem cell transplantation. ASH 2016 Annual Meeting, 2016. e-Pub 2016.
28. Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, mCDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, Geroge S. Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. American Society for Clinical Oncology, 2016. e-Pub 2016.
29. Reilley M, Blando J, Katkhuda R, Menter D, Sharma P, Allion J, Kopetz S, Maru D, Overman M. Immunologic profiling of consensus molecular subtype (CMS) stratified colorectal cancer (CRC) primary and liver metastatectomy specimens: Implications for immune targeting of proficient mismatch repair CRC. American Society for Clinical Oncology, 2016. e-Pub 2016.
30. Janjigian Y, Bendell J, Calvo E, Kim JW, Ascierto P, Sharma P, Ott PA, Bono P, Jaeger D, Evans J, Braud F, Chau I, Tschaika M, Harbison C, Lin CS, Le DT. CheckMate-032: phase 1/2, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). American Society for Clinical Oncology, 2016. e-Pub 2016.
31. Bajorin DF, |Sharma P, Quinn DI, Plimack ER, Hoffman-Censits JH, O'Donnell PH, Siefker-Radtke AO, Sheikh NA, LlllJS, Trager JB, Gomella LG. Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patietnts (pts). American Society for Clinical Oncology, 2016. e-Pub 2016.
32. Fuji T, Colen R, Bilen AM, Hess K, Hajjar J, Suarez-Almazor ME, Hong DS, Janku F, Subbiah V, Kato S, Karp DD, Piha-Paul SA, Tsimberidou AM, Fu S, Sharma P, Meric-Bernstam F, Naing A. Incidence of Immune-related adverse events in patients who received immunotherapy and radiographic analysis to predict pneumonitis. American Society for Clinical Oncology, 2016. e-Pub 2016.
33. Reilley M, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Zinner R, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong D. Phase I clinical trial of combination Imatinib and Ipilimumab in patients with advanced malignancies. American Society for Clinical Oncology, 2016. e-Pub 2016.
34. Daver N, Basu S, Guillermo GM, Cortes J, Ravando F, Komblau S, Konopleva M, Andreeff M, Borthakur G, Jain N, Wierda W, Ruvolo P, Matthews J, Flores W, Yang H, Verstovsek S, Bueso-Ramos C, Somani N, Blando J, Allison J, Kantarjan H, Sharma P. Defining the immune checkpoint landscape of acute myeloid leukemia (AML). American Association for Cancer Research, 2016. e-Pub 2016.
35. Uemura MI, Haymaker C, James M, Cornfeld M, Chunduru S, Agrawal S, Hwu WJ, Davies M, Glitza IC, Patel SP, Amaria R, Yee C, Tawbi HA, Woodman SE, Hwu P, Sharma P, Allison J, Hailemichael Y, Bernatchez C, Diab A. A phase 1/2, open-label, single-institution study of intratumoral IMO-2125 in combination with systemic ipilimumab in patients with metastatic melanoma. American Society for Clinical Oncology, 2016. e-Pub 2016.
36. Motzer RJ, Sharma P, Escudier B, McDermott D, Geroge S, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Nathan P, Grunwald V, Tomita Y, Zhao H, Waxman IM, Hammers HJ. Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study. American Society for Clinical Oncology, 2016. e-Pub 2016.
37. Sharma P, Bono P, Kim J, Spiliopoulou, Calvo E, Pillai R, Ott P, DeBraud F, Morse M, Le D, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg J. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. American Society for Clinical Oncology, 2016. e-Pub 2016.
38. Subudhi S, Aparicio A, Troncosco P, Zhang J, Gumbs C, Wu CJ, Logothetis CJ, Futreal A, Allison J, Sharma P. A Feasibility study to Determine T Cell Responses to Neoantigens Following Treatment with Ipilimumab in Men with Metastatic Castration-resistant Prostate Carcinoma(mCRPC). American Society for Clinical Oncology, 2016. e-Pub 2016.
39. Bilen MA, Hess K, Aparicio A, Kim J, Zurita A, Pagliaro LC, Araujo J, Corn P, Atkinson B, Tannir N, Sharma P, Lin SH, Logothetis CJ, Tu SM. Sipuleucel-T cellular immunotherapy: clinical predictors of cancer-specific death in patients with castration-resistant prostate cancer (CRPCa). American Society for Clinical Oncology, 2016. e-Pub 2016.
40. Massarelli E, Parra E, Diao L, Wang J, Jaime RC, Behrens C, Blando J, Byers L, Wistuba I, Sharma P, Allison J, Heymach J. High OX-40 expression on the tumor immune infiltrate is a prognostic factor of better overall survival in non-small cell lung cancer. American Association for Cancer Research - CRI-CIMT-EATI International Cancer Immunotherapy Conference, 2016. e-Pub 2016.
41. Goswami S, Zhao H, Zhang X, Sharma P. Epigenetic changes in T cells in response to immune checkpoint blockade. American Society for Clinical Oncology, 2016. e-Pub 2016.
42. Daver N, Basu S, Cortes J, Ravandi F, Garcia-Manero G, Jabbour E, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Borthakur G, Pemmaraju N, Bueso-Ramos C, Blando J, allison J, Kantarjian H, Sharma P. Lirilumab in Combination with Azacytidine in Patients with Relapsed Acute Myeloid Leukemia. ASH 2016 Annual Meeting, 2016. e-Pub 2016.
43. Van M, Ciombor KK, Salem M, Nimeiri HS, Iqbal S, Singh PP, Polite B, Deming S, Chan E, Wade III JL, Bekaii-Saab T, Uronis H, Pasia M, Bland G, Wolff R, Ohinata A, Ohaji C, Rogers J, Sharma P, Eng C. A Multi-Institutional ETCTN Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (SCCA). American Society for Clinical Oncology, 2016. e-Pub 2016.
44. Morris V, Mahvash A, Vence L, Blando J, Wolff R, Ohinata A, Ohaji C, Allison J, Sharma P, Eng C. A Phase II Study of Nivolumab in refactory Metastatic Squamous Cell Carcinoma of the Anal Canal: Immunologic correlates of response. American Association for Cancer Research, 2016. e-Pub 2016.
45. Daver N, Cortes J, Ravandi F, Basu S, Garcia-Manero G, Jabbour E, Hendrickson S, Pierce S, Ning J, Konopleva M, Andreeff M, Borthakur G, Pemmaraju N, Bueso-Ramos C, Blando J, Allison J, Kantarjian H, Sharma P. Nivolumab in Combination with Azacytidine in Patients with Relapsed Acute Myeloid Leukemia. ASH 2016 Annual Meeting, 2016. e-Pub 2016.
46. Subudhi S, Aparicio A, Gao JJ, Zurita-Saavedral A, Araujo J, Logothetis CJ, Brindal K, Allison JA, Vence S, Sharma P. Exploratory biomarkers that predict for clinical outcomes in a Phase II trial with ipilimumab plus finite androgen deprivation therapy for metastatic non-castrate prostate cancer. American Association for Cancer Research, 2016. e-Pub 2016.
47. Tang C, Welsh J, Groot P, Massarelli E, Chang J, Hess K, Curran M, Cabanillas M, Subbiah V, Fu S, Tsimberidou A, Karp DD, Gomez DR, Komaki R, Sharma P, Naing A, Hong DS. Phase I trial combining ipilimumab + high dose stereotactic radiation: results and serum immune correlates. American Society for Clinical Oncology, 2016. e-Pub 2016.
48. Sharma P. From the clinic to the lab: Investigating immune responses to immune checkpoint therapies. 22nd Annual International Cancer Immunotherapy Symposium, 2014. e-Pub 2014.
49. Gao JJ, Chen H, Ng Tang D, Sharma P. Investigating genes and pathways that play a role in immune responses mediated by anti-CTLA-4 therapy. American Society of Clinical Oncology, 2012. e-Pub 2012.
50. Gao JJ, Sun J, Ward J, Rao P, Troncoso P, Araujo J, Ng Tang D, Chen H, Thall P, Wen S, Sharma P. Combination therapy with anti-CTLA-4 plus leuprolide acetate in the pre-surgical setting of patients with regional, high-risk prostate cancer. American Association for Cancer Research, 2012. e-Pub 2012.
51. Sharma P. Novel Approaches to Assessing T-Cell Function and Reactivity. American Society for Clinical Oncology 2012 Markers in Cancer, 2012. e-Pub 2012.
52. Sharma P. Investigating the role of the ICOS/ICOSL pathway in mediating anti-tumor responses in the setting of CTLA-4 blockade. Penn State College of Medicine, Penn State Hershey Cancer Institute, 2012. e-Pub 2012.
53. Aparicio A, Sun JJ, Ng Tang D, Arap W, Araujo J, Corn P, Tannir N, Wang X, Sharma P. A Phase II Study of Ipilimumab Plus Androgen Deprivation Therapy in Castration-sensitive Prostate Carcinoma. American Association for Clinical Research, 2012. e-Pub 2012.
54. Bajorin DF, Sharma P, Sims RB, Sandler A, Lerner SP. Design of a Phase 2 randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence. American Society of Clinical Oncology, 2012. e-Pub 2012.
55. Sharma P. Immunology: From Bench to Bedside and Back. Translational Science: From Bench to Bedside and Back, MD Anderson Cancer Center Department of Investigational Cancer Therapeutics, 2011. e-Pub 2011.
56. Sharma P. Anti-CTLA-4 therapy requires the ICOS/ICOSL pathway to mediate optimal anti-tumor responses. Center for Immune Modulatory Therapies for Autoimmunity and Cancer, Karolinska Institutet, Ljusterö, Sweden, 2011. e-Pub 2011.
57. Sharma P. Novel agents and targets in immunotherapy. First Annual Kidney Cancer Collaborative Symposium, MD Anderson Cancer Center Kidney Multidisciplinary Research Program, 2011. e-Pub 2011.
58. Sharma P. Immune monitoring of CTLA-4 blockade on a pre-surgical clinical trial: Implicating the ICOS/ICOSL pathway in anti-tumor immune responses. Hematology and Medical Oncology Grand Rounds, Memorial Sloan-Kettering Cancer Center, 2011. e-Pub 2011.
59. Sharma P. Implicating the ICOS/ICOSL Pathway as a Target for Cancer Immunotherapy. Clinical Immunology Society, 2011. e-Pub 2011.
60. Sharma P. Investigating the ICOS/ICOSL pathway as a target to improve anti-tumor responses mediated by CTLA-4 blockade. Translational Research Seminar, Mt. Sinai School of Medicine, 2011. e-Pub 2011.
61. Sharma P. Management of Metastatic Clear Cell RCC (1) Immunotherapeutic Approaches, Old and New. MD Anderson Cancer Center Department of Genitourinary Medical Oncology Courses on Renal Cell Carcinoma, 2011. e-Pub 2011.
62. Sharma P. CTLA-4 and ICOS as cancer immunotherapy targets. American Association for Cancer Research, 2011. e-Pub 2011.
63. Sharma P. Immunologic Consequences of Renal Ablation and Rationale for Combination Renal Ablation/Immunomodulation Strategies. MD Anderson Cancer Center Kidney Multidisciplinary Research Program, 2011. e-Pub 2011.
64. Sharma P. Pre-operative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Canadian Society of Immunology, 2010. e-Pub 2010.
65. Sharma P. Pre-surgical Clinical Trials in Cancer Patients to Identify Biomarkers of Immunotherapy. Clinical Immunology Society, 2010. e-Pub 2010.
66. Sharma P. Role of ICOS-expressing T Cells in Anti-tumor Responses Mediated by CTLA-4 Blockade. Basic Science Distinguished Lecturer Program, Washington University School of Medicine, 2010. e-Pub 2010.
67. Sharma P. Monitoring Immune and Clinical Responses to Anti-CTLA-4 Therapy. University of Connecticut Center for Immunotherapy of Cancer and Infectious Diseases, Health Center Seminar Series, 2010. e-Pub 2010.
68. Sharma P. Defining the Role of Inducible Co-stimulator (ICOS)-Expressing T Cells Against Melanoma. Melanoma Research Association, 2010. e-Pub 2010.
69. Sharma P. Prostate Cancer Immunotherapy: Immune Responses Mediated by CTLA-4 Blockade. Free University Amsterdam Prostate Cancer Symposium, 2010. e-Pub 2010.
70. Sharma P. Pre-operative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Department of Immunology Seminar, Ontario Cancer Institute, Princess Margaret Hospital, 2010. e-Pub 2010.
71. Sharma P. Immune monitoring of CTLA-4 blockade on a pre-surgical clinical trial: Implicating the ICOS/ICOSL pathway in anti-tumor immune responses. American Association for Cancer Research - Tumor Immunology, 2010. e-Pub 2010.
72. Sharma P. Assessment of biologic impact of immunotherapeutic agents. American Association for Cancer Research, 2010. e-Pub 2010.
73. Sharma P. Immunologic Impact of Anti CTLA-4 Therapy. American Association for Cancer Research Annual Meeting, 2009. e-Pub 2009.
74. Sharma P. Is there Still a Role for Immunotherapy in the Treatment of Metastatic Renal Cell Carcinoma. MD Anderson Cancer Center - Urology Oncology Conference, 2009. e-Pub 2009.
75. Sharma P. Assessment of Biologic Impact of Immunotherapeutic Agents. American Association for Cancer Research Molecular Biology Clinical Oncology Workshop, 2009. e-Pub 2009.
76. Sharma P. Immune responses mediated by CTLA-4 blockade. ABCAM Immune Tolerance in Cancer and Autoimmune Disease Conference, 2009. e-Pub 2009.
77. Sharma P. Systemic Chemotherapy for Urothelial Carcinoma. MD Anderson Cancer Center 9th Annual Oncology Update: Advances and Controversies, 2009. e-Pub 2009.
78. Sharma P. Immunize Responses Mediated by CTLA-4 Blockade. Keystone Symposia: Mobilizing Cellular Immunity for Cancer Therapy, 2009. e-Pub 2009.
79. Sharma P. Immune Responses Mediated by CTLA-4 Blockade. Melanoma Research Alliance Annual Meeting, 2009. e-Pub 2009.
80. Sharma P. Immunologic Impact of Anti-CTLA-4 Therapy. American Society of Clinical Oncology Annual Meeting, 2009. e-Pub 2009.
81. Sharma P, Kamat A, Ng Tang D, Chen H, Fu T, Sun J, Troncoso P, Yuan J, Wolchok J, Queada S, Logothetis C, Allison J. Assessing immunologic impact of anti-CTLA-4 therapy on a presurgical clinical trial. Proc Amer Assoc Can Res:Abstr 5665, 2009. e-Pub 2009.
82. Sharma P. Immune Responses Mediated by CTLA-4 Blockade. American Association for Cancer Research Annual Meeting, Plenary Session, 2008. e-Pub 2008.
83. Sharma P. Immunologic Impact of Anti-CTLA-4 Therapy. Cancer Research Institute Annual Meeting, 2008. e-Pub 2008.
84. Sharma P. Functional and Phenotypic Impact of Anti-CTLA-4 Antibody in the Pre-surgical Setting. American Association for Cancer Research Annual Meeting, 2008. e-Pub 2008.
85. Sharma P. Immunotherapy for Renal Cell Carcinoma. MD Anderson Cancer Center, 2008. e-Pub 2008.
86. Sharma P. Immunology Impact of Anti-CTLA-4 Antibody in a Neoadjuvant Setting. Cancer Research Institute Annual Meeting, 2007. e-Pub 2007.
87. Sharma P. Monitoring Immune Response in Patients Treated with Immunotherapy, Physician-Scientist/Clinician Investigator Update. MD Anderson Cancer Center Pioneers Group, 2007. e-Pub 2007.
88. Sharma P. Studying Immune Responses to the NY-ESO-1 Antigen in Transitional Cell Carcinoma Patients. MD Anderson Cancer Center Genitourinary Medical Oncology Bladder SPORE, 2007. e-Pub 2007.
89. Sharma P. Immunotherapy for Prostate Cancer. Prostate Cancer Foundation Annual Meeting, 2007. e-Pub 2007.
90. Sharma P. Regulatory T-cells Are Increased in the Tumor Microenvironment of Prostate Cancer Patients. Cancer Research Institute Annual Meeting, 2006. e-Pub 2006.
91. Sharma P. CD8+ Tumor-Infiltrating Lymphocytes as a Statistically Significant Marker of Disease Recurrence and Survival in Transitional Cell Carcinoma Patients. American Society of Clinical Oncology Annual Meeting, 2006. e-Pub 2006.
92. Sharma P. Immunological Studies in Prostate Cancer. MD Anderson Cancer Center - Center for Cancer Immunology, 2006. e-Pub 2006.
93. Sharma P. Combinatorial Targeting of the NY-ESO-1 Cancer Testis Antigen. Cancer Research Institute Annual Meeting, 2005. e-Pub 2005.
94. Sharma P. Protein and DNA-based Vaccines with the NY-ESO-1 Antigen in Cancer Patients. National Cancer Institute Center of Excellence in Immunology, 2005. e-Pub 2005.
95. Sharma P. Protein and DNA-based Vaccines With NY-ESO-1 Antigen in Cancer Patients. International Society for Biological Therapy of Cancer Annual Meeting, 2005. e-Pub 2005.

Book Chapters

1. Campbell MT, Sharma A, Goswami S, Sharma P. Tumor Immunotherapy. In: Clinical Immunology: Principles and Practice, 5th Edition, 2016.
2. Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. In: Annu Rev Med. 71-90, 71-90, 2013.
3. Callahan MK, Wolchok JD, Allison JP, Sharma P. Immune Co-signaling to Treat Cancer. In: Cancer Immunotherapy: Paradigms, Practice and Promise. 211-280. Springer, 211-280, 2013.
4. Peggs KS, Quezada SA, Sharma P, Allison JP. Chapter 13: Cancer Immunotherapy. In: Cancer Medicine 9th Edition, 2010.